By a News Reporter-Staff News Editor at Cancer Weekly -- As MolecularHealth readies for the launch of TreatmentMAP, its cancer treatment decision support platform, the company has signed three additional members to its advisory board. The new board members, who bring decades of experience in oncology and patient support, will join eight others already appointed (see also MolecularHealth).
Stephen Jones, M.D., has been involved in clinical research and oncology for over 40 years, studying 17 new drugs or combinations that have been approved for cancer treatment by the FDA. Most recently, he served as the medical director of research for US Oncology Research from 1999 to 2014, during which time he also was chair of breast cancer research and emeritus partner in Texas Oncology. Dr. Jones received his medical degree from Case Western Reserve School of Medicine in Cleveland, Ohio and completed residency and fellowship training in medical oncology at Stanford.
"There are a number of companies out there that can run lab tests and provide reports back to physicians, but the reality is many of those reports are unhelpful. Physicians are looking for the bottom line: 'How is this information going to help my patient?'" said Dr. Jones. "MolecularHealth has the platform to develop and deliver the bottom line better than anybody else. In my opinion, its innovative bioinformatics and computing capabilities are the most advanced in the world."
Thomas Kean, MPH, has 35 years of experience working to prevent and control chronic disease, serving across multiple sectors, including government, not-for-profit and for profit institutions. Kean is the CEO and president of C-Change, a coalition of leaders from organizations representing the public, private and voluntary sectors devoted to eliminating the burden of cancer on the US population. Kean received a BA in psychology from the University of Texas, where he also received his MPH in urban health.
"What the industry needs is a timely way to deliver physicians the right information that will help them and their patients make good clinical decisions with positive and effective outcomes," said Kean. "With the ability to map the genome, we're creating tons of new information at an exponential rate. However, the challenge of the genomic revolution is how to synthesize this information and put it together in an actionable way. MolecularHealth has created a promising approach for making that happen in a timely and accurate fashion."
Kathleen Lokay is president and CEO of Via Oncology, an affiliate company of University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh Cancer Institute. Since joining UPMC in 2008, Lokay has worked with Via Oncology to assist oncologists with ensuring value-based care, focusing on improving the quality and efficiency of cancer care. Lokay began her career as a certified public accountant and holds a BBA in accounting from the University of Texas at Austin.
"One of MolecularHealth's strategies is to work more on the community side of oncology, where I see a gap in the market right now," said Lokay. "MolecularHealth's ability to engage and provide for community physicians as a trusted partner gives them the kind of support they need to interpret what genomic markers mean for their patients. I think the community approach is a differentiator and supports a niche that, outside of academic institutions, is otherwise open."
Lloyd Everson, M.D., CEO of MolecularHealth, added, "I speak for the whole executive team when I say that we are honored to welcome Dr. Jones, Mr. Kean and Ms. Lokay to the advisory board. Each new member boasts admirable careers in the fields of cancer research, prevention and patient support. Their combined experiences and knowledge will be an indispensable resource to MolecularHealth as we continuously work to improve our offering." ABOUT MOLECULARHEALTH MolecularHealth delivers on the promise of personalized, precision medicine. By using advanced proprietary information technologies to sift through terabytes of genetic and molecular test findings in a fraction of the time needed for current manual analysis, MolecularHealth provides doctors and patients with faster, more accurate insights into the role genes play in the progression and treatment of an individual's cancer. Eight years in development by a multidisciplinary team of doctors, scientists and IT experts, MolecularHealth works in partnership with some of the world's leading healthcare and information technology companies, including the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). The company has a CLIA-certified NGS lab and headquarters in The Woodlands, Texas as well as locations in Boston, Mass. and Heidelberg, Germany. Website: www.molecularhealth.comBlog: www.molecularhealth.com/blogTwitter:www.twitter.com/molecularhealthLinkedIn:www.linkedin.com/company/molecularhealthYouTube:www.youtube.com/user/MolecularHealthInc
Keywords for this news article include: Cancer, Genetics, Oncology, MolecularHealth.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC